Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results
Open Access
- 24 September 2022
- journal article
- research article
- Published by Springer Nature in npj Vaccines
- Vol. 7 (1) , 1-11
Abstract
Despite the successful deployment of efficacious vaccines and therapeutics, the development of novel vaccines for SARS-CoV-2 remains a major goal to increase vaccine doses availability and accessibility for lower income setting. We report here on the kinetics of Spike-specific humoral and T-cell response in young and old volunteers over 6 months follow-up after a single intramuscular administration of GRAd-COV2, a gorilla adenoviral vector-based vaccine candidate currently in phase-2 of clinical development. At all three tested vaccine dosages, Spike binding and neutralizing antibodies were induced and substantially maintained up to 3 months, to then contract at 6 months. Potent T-cell responses were readily induced and sustained throughout the study period, with only minor decline. No major differences in immune response to GRAd-COV2 vaccination were observed in the two age cohorts. In light of its favorable safety and immunogenicity, GRAd-COV2 is a valuable candidate for further clinical development and potential addition to the COVID-19 vaccine toolbox to help fighting SARS-CoV-2 pandemic.Keywords
Funding Information
- Regione Lazio,Italian Ministry of research
- Ministry of Health, Italy | Agenzia Italiana del Farmaco, Ministero della Salute (Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1, Ricerca corrente line1)
- Regione Lazio, Italian Ministry of research
This publication has 72 references indexed in Scilit:
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Age-Related Decline in Primary CD8+ T Cell Responses Is Associated with the Development of Senescence in Virtual Memory CD8+ T CellsCell Reports, 2018
- Pseudotype Neutralization Assays: From Laboratory Bench to Data AnalysisMethods and Protocols, 2018
- Chimpanzee adenoviral vectors as vaccines – challenges to move the technology into the fast laneExpert Review of Vaccines, 2017
- Prime-boost vaccine strategy against viral infections: Mechanisms and benefitsVaccine, 2016
- Optimizing vaccine-induced CD8+T-cell immunity: focus on recombinant adenovirus vectorsExpert Review of Vaccines, 2011
- Viruses as vaccine vectors for infectious diseases and cancerNature Reviews Microbiology, 2009
- Heterologous prime–boost vaccinations for poverty-related diseases: advantages and future prospectsExpert Review of Vaccines, 2009
- Adenoviruses as vaccine vectorsMolecular Therapy, 2004